Equity Profile

EXEL

Exelixis, Inc.

Health CareBiotechnology$12.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.86

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$636M

Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. With a market cap of $13 billion, it plays a significant role in the healthcare sector, particularly in oncology, which is a growing area of medical research and treatment.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In the last quarter, Exelixis reported an EPS of $0.87, significantly beating expectations of $0.67. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Continued focus on expanding its oncology portfolio.
Commitment to advancing clinical trials for new therapies.
Efforts to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Exelixis's upcoming earnings, expecting solid performance based on historical trends. The consensus EPS of $0.86 reflects confidence in the company's ability to maintain profitability.

Bull Case

If Exelixis exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations, it may raise concerns about its growth prospects and market competition, leading to a negative stock reaction.

Key Metrics to Watch

EPS

$0.86

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$636M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.86?

A beat on EPS could reinforce investor confidence in Exelixis's growth trajectory and operational efficiency.

What are the revenue figures relative to the consensus of $636M?

Revenue performance will indicate market demand for Exelixis's products and its competitive position in the oncology space.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Exelixis's ability to leverage its recent product launches effectively, leading to higher-than-expected revenue growth.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

Options pricing suggests a relatively low expected move, which may not reflect the potential for significant upside.

Recent trends in oncology treatments suggest increasing demand that could benefit Exelixis's product portfolio.

Key Risk

If revenue significantly exceeds $636M, it could challenge the current bearish sentiment and validate the bullish thesis.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Exelixis's ability to sustain its recent earnings momentum amid competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $0.90 or higher would confirm the bull case, indicating strong product demand and cost management.

Bear Confirmed If

An EPS below $0.80 would confirm the bear case, raising concerns about growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.04%

Historical Avg

±1.1%

In line with history

The options market is pricing in a modest move around earnings, suggesting that investors expect some volatility but not a major shift in stock price.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests the stock could rise by an average of 1.14% on the day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of 0.79% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Any commentary on competitive pressures in the oncology market.
3Insights into the sales performance of recently launched products.
4Management's outlook on future revenue growth.
5Details on cost management strategies and operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.86

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$636M

Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In the last quarter, Exelixis reported an EPS of $0.87, significantly beating expectations of $0.67. The stock reacted positively, gaining 0.57% the following day.

Management Promises & Guidance

Continued focus on expanding its oncology portfolio.
Commitment to advancing clinical trials for new therapies.
Efforts to enhance operational efficiency.

Expectations

Wall Street Expectations

Bull Case

If Exelixis exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations, it may raise concerns about its growth prospects and market competition, leading to a negative stock reaction.

Key Metrics to Watch

EPS

$0.86

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$636M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.86?

A beat on EPS could reinforce investor confidence in Exelixis's growth trajectory and operational efficiency.

What are the revenue figures relative to the consensus of $636M?

Revenue performance will indicate market demand for Exelixis's products and its competitive position in the oncology space.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Exelixis's ability to leverage its recent product launches effectively, leading to higher-than-expected revenue growth.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

Options pricing suggests a relatively low expected move, which may not reflect the potential for significant upside.

Recent trends in oncology treatments suggest increasing demand that could benefit Exelixis's product portfolio.

Key Risk

If revenue significantly exceeds $636M, it could challenge the current bearish sentiment and validate the bullish thesis.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Exelixis's ability to sustain its recent earnings momentum amid competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $0.90 or higher would confirm the bull case, indicating strong product demand and cost management.

Bear Confirmed If

An EPS below $0.80 would confirm the bear case, raising concerns about growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.04%

Historical Avg

±1.1%

In line with history

The options market is pricing in a modest move around earnings, suggesting that investors expect some volatility but not a major shift in stock price.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests the stock could rise by an average of 1.14% on the day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of 0.79% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Any commentary on competitive pressures in the oncology market.
3Insights into the sales performance of recently launched products.
4Management's outlook on future revenue growth.
5Details on cost management strategies and operational efficiency.